

# 中华肿瘤杂志<sup>®</sup>


ZHONGHUA ZHONGLIU ZAZHI

2008年3月 第30卷 第3期

## CHINESE JOURNAL OF ONCOLOGY

Volume 30 Number 3

March 2008



中华医学会  
CHINESE  
MEDICAL  
ASSOCIATION

ISSN 0253-3766





# 中华肿瘤杂志®

CHINESE JOURNAL OF ONCOLOGY

月刊 1979年3月创刊 第30卷 第3期 2008年3月23日出版

## 中国科协精品科技期刊工程项目资助期刊

主管  
中国科学技术协会

主办  
中华医学会  
100710,北京市东四西大街42号

编辑  
中华肿瘤杂志编辑委员会  
100021,北京市朝阳区潘家园南里17号  
电话(传真):0086-10-67788231  
E-mail: chinjoncol@yahoo.com.cn  
http://www.medline.org.cn

总编辑  
赵平

编辑部主任  
谭颖波

出版  
中国医学科学院肿瘤医院  
肿瘤研究所  
100021,北京市朝阳区潘家园南里17号  
电话:0086-10-67781331

广告  
中华肿瘤杂志编辑部  
100021,北京市朝阳区潘家园南里17号  
电话(传真):0086-10-67762118

广告经营许可证  
京东工商广字第0149号

印刷  
北京集惠印刷有限责任公司

发行  
国内:北京报刊发行局  
国外:中国国际图书贸易总公司  
(北京399信箱,100044)  
代号M99

订购  
全国各地邮电局  
邮发代号2-47

邮购  
中华肿瘤杂志编辑部  
100021,北京市朝阳区潘家园南里17号  
电话:0086-10-67788231,67762118  
E-mail: chinjoncol@yahoo.com.cn

定价  
每期18.00元,全年216.00元

中国标准连续出版物号

ISSN 0253-3766  
CN 11-2152/R

2008年版权归中华医学会所有

除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点

本刊如有印装质量问题,请向本刊编辑部调换

## 目次

### 专题综述

老年人乳腺癌治疗的研究现状与展望 ..... 张保宁 张慧明 161

### 基础研究

黏附分子 $\alpha v\beta 3$ 和 $\alpha v\beta 5$ 介导肿瘤细胞与  
肿瘤内皮细胞的黏附 ..... 牛纪晓 张文健 叶丽亚等 165

重组肿瘤抑素血管生成抑制相关肽对  
裸鼠移植性卵巢癌的抑制作用 ..... 张广美 隋丽华 贾彤等 170

表达CD40L基因的卵巢癌细胞诱导  
树突状细胞成熟及分泌Th1型细胞  
因子的作用机制 ..... 张正茂 张风华 王喜梅等 174

人微管不稳定蛋白基因真核表达载体的  
构建与表达及对食管癌细胞的作用 ..... 王峰 王留兴 王瑞林等 179

核苷酸切除修复交叉互补基因1与卵巢癌  
顺铂耐药的关系 ..... 刘国艳 瞿全新 糜若然等 184

三氧化二砷联合丁硫氨酸亚砷胺诱导  
人白血病K562/ADM细胞凋亡 ..... 王涛 马梁明 张华屏等 188

### 临床研究

B7-H1及其受体PD-1在胃癌组织中的表达  
与意义 ..... 刘书漫 孟青 张钦宪等 192

三阴性乳腺癌的临床病理特征及预后分析 ..... 关印 徐兵河 196

原发乳腺非霍奇金淋巴瘤的预后分析 ..... 郭海宜 赵欣旻 曹军宁等 200

早期乳腺癌乳头乳晕复合体隐匿癌浸润的  
临床病理研究 ..... 王圣应 彭德峰 蔡兆根等 203

保乳术后自主呼吸控制部分乳腺外照射  
靶区位移的研究 ..... 李建彬 张琳 卢洁等 207

p16<sup>INK4a</sup>在宫颈液基细胞学辅助筛查中的  
标记意义 ..... 徐婷 陆惠娟 何以丰 211

### 临床应用

唑来膦酸治疗实体瘤骨转移或多发性骨髓瘤  
中重度骨痛的Ⅲ期临床研究 ..... 董梅 冯奉仪 张阳等 215

吉非替尼单药维持治疗晚期非小细胞肺癌的疗效和安全性分析 .....	王孟昭 钟巍 张力等	221
FOLFIRI 方案二线治疗复发或转移性结直肠癌 .....	李健 徐建明 李洁等	225
纳米炭在微创肺癌淋巴结清扫术中的应用 .....	李树本 何建行 陈汉章等	228
胰腺癌术中组织活检及细胞学诊断的临床意义 .....	赵东兵 汪毅 单毅等	231
乳管内视镜定位在乳导管解剖术中的应用 .....	徐晓洲 王靖 王仲照等	234
多层螺旋 CT 肠腔充气扫描及图像重建技术对大肠癌的诊断价值 .....	陈刚 许彪 夏涛等	237

**病例报告**

肝癌生存 43 年一例 .....	马曾辰 吴肇光 汤钊猷	210
-------------------	-------------	-----

**读者·作者·编者**

关于论文写作中的作者署名与志谢 .....		164
关于一稿两投和重复发表问题的处理原则 .....		214
本刊对来稿中统计学处理的有关要求 .....		220

**简 讯**

本刊两篇论文喜获第五届中国科学技术协会期刊特别优秀学术论文奖和优秀学术论文奖 .....		173
“证实 CASP8 基因启动子的一个六核苷酸插入/缺失多态与多种癌症易感性相关” .....		
入选 2007 年度中国基础研究十大新闻 .....		199
第二届中国肿瘤内科大会第一轮会议及征文通知 .....		224
第六届全国难治性白血病学术研讨会征文通知 .....		227
国际中医中西医结合肿瘤学术交流大会暨第十一届全国中西医结合肿瘤学术大会征文通知 .....		230
中国抗癌协会妇科肿瘤专业委员会高级医师研讨会征文通知 .....		233
第七届全国大肠癌学术会议暨第十届广东省大肠癌学术会议征文通知 .....		236
研究近讯 .....	英文目次后	

**本刊稿约见本卷第 1 期第 79 页**

**本期责任编辑**     王书亚

# CHINESE JOURNAL OF ONCOLOGY

Monthly

Established in March 1979

Volume 30, Number 3

March 23, 2008

## Responsible Institution

China Association for Science  
and Technology

## Sponsor

Chinese Medical Association  
42 Dongsi Xidajie, Beijing 100710, China

## Editing

Editorial Board of Chinese  
Journal of Oncology  
17 Panjiayuan Nanli, Chaoyang District,  
Beijing 100021, China  
Tel(Fax): 0086-10-67788231  
E-mail: chinjoncol@yahoo.com.cn  
http://www.medline.org.cn

## Editor-in-Chief

ZHAO Ping(赵平)

## Managing Director

TAN Ying-bo(谭颖波)

## Publishing

Cancer Institute & Hospital  
Chinese Academy of Medical  
Sciences  
17 Panjiayuan Nanli, Chaoyang District,  
Beijing 100021, China  
Tel:0086-10-67781331

## Printing

Beijing Jihui Press, Limited  
(Liability) Company

## Overseas Distributor

China International Book  
Trading Corporation  
P. O. Box 399, Beijing 100044, China  
Code No. M99

## Mail-Order

Editorial Office, Chinese  
Journal of Oncology  
17 Panjiayuan Nanli, Chaoyang District,  
Beijing 100021, China  
Tel:0086-10-67788231, 67762118  
E-mail: chinjoncol@yahoo.com.cn

## CSSN

ISSN 0253-3766  
CN 11-2152/R

## Copyright © 2008 by the Chinese Medical Association

All articles published represent the opin-  
ions of the authors, do not reflect the offi-  
cial policy of the Chinese Medical Associ-  
ation or the Editorial Board, unless this is  
clearly specified.

## CONTENTS IN BRIEF

### REVIEWS

- Current status and perspective in treatment of breast cancer in elderly women** ..... 161  
*ZHANG Bao-ning, ZHANG Hui-ming*

### BASIC RESEARCH

- Tumor cell-tumor endothelial cell adhesion mediated by  $\alpha v \beta 3$  and  $\alpha v \beta 5$  molecules** ..... 165  
*NIU Ji-xiao, ZHANG Wen-jian, YE Li-ya, et al*
- Inhibitory effect of recombinant anti-angiogenic peptide of Tumstatin on growth and metastasis of human ovarian cancer transplanted in nude mice** ..... 170  
*ZHANG Guang-mei, SUI Li-hua, JIA Tong, et al*
- Enhanced expression of CD40L cDNA on ovarian cancer cell line OVHM induces the secretion of Th1 cytokines from dendritic cells** ..... 174  
*ZHANG Zheng-mao, ZHANG Feng-hua, WANG Xi-mei, et al*
- Construction and expression of human stathmin gene eukaryotic expression vector and its effect on esophageal cancer cells** ..... 179  
*WANG Feng, WANG Liu-xing, WANG Rui-lin, et al*
- Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer** ..... 184  
*LIU Guo-yan, QU Quan-xin, MI Ruo-ran, et al*
- Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro** ..... 188  
*WANG Tao, MA Liang-ming, ZHANG Hua-ping, et al*

### CLINICAL INVESTIGATIONS

- Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma** ..... 192  
*LIU Shu-man, MENG Qing, ZHANG Qin-xian, et al*
- Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases** ..... 196  
*GUAN Yin, XU Bing-he*
- Prognosis of primary non-Hodgkin's lymphoma of the breast** ..... 200  
*GUO Hai-yi, ZHAO Xin-min, CAO Jun-ning, et al*
- Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma** ..... 203  
*WANG Sheng-ying, PENG De-feng, CAI Zhao-gen, et al*
- Study on the target movement in external-beam partial breast irradiation with active breathing control after breast-conserving surgery** ..... 207  
*LI Jian-bin, ZHANG Lin, LU Jie, et al*
- Role of p16<sup>INK4a</sup> as a biomarker in liquid-based cervical cytology screening** ..... 211  
*XU Ting, LU Hui-juan, HE Yi-feng*

### CLINICAL APPLICATIONS

- Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma** ..... 215  
*DONG Mei, FENG Feng-yi, ZHANG Yang, et al*

<b>Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer</b> .....	221
<i>WANG Meng-zhao, ZHONG Wei, ZHANG Li, et al</i>	
<b>Irinotecan plus fluorouracil /leucovorin ( FOLFIRI ) as a second line chemotherapy for refractory or metastatic colorectal cancer</b> .....	225
<i>LI Jian, XU Jian-ming, LI Jie, et al</i>	
<b>Injection of activated carbon nanoparticles for guiding lymphadenectomy during minimal invasive surgery in lung cancer</b> .....	228
<i>LI Shu-ben, HE Jian-xing, CHEN Han-zhang, et al</i>	
<b>Value of intraoperative fine-needle aspiration cytology and histopathologic biopsy in the diagnosis of pancreatic cancer</b> .....	231
<i>ZHAO Dong-bing, WANG Yi, SHAN Yi, et al</i>	
<b>A comparison of localization by ductoscopy-guided wire and conventional methods in terminal duct excision for women with pathological nipple discharge</b> .....	234
<i>XU Xiao-zhou, WANG Jing, WANG Zhong-zhao, et al</i>	
<b>Diagnostic value of MSCT pneumocolon and image reconstruction in colorectal carcinoma</b> .....	237
<i>CHEN Gang, XU Biao, XIA Tao, et al</i>	

---

## Research News

### Cancer immunoediting

The immune system plays a crucial role in shaping cancer development. It is able to detect early lesions through immuno-surveillance and eliminate them. It is thought to maintain tumors in a state of equilibrium. Tumor cells with either reduced immunogenicity or with increased capacity to attenuate the immune response can escape the equilibrium and progress. This whole process is termed cancer immunoediting. Clear evidence for this state has been produced by Mark Smith et al. (Nature, 2007). The authors used C57BL/6 and 129/SvEv mouse colonies and injected with 3'-methylcholanthrene (MCA) to induce sarcoma. As the authors were only interested in the mice that did not develop progressively growing tumors, they eliminated from the study all mice that had expanding tumors by 200 days. Mice that had only small stable mass at the injection site were then treated with control Ig or a mixture of monoclonal antibodies to deplete CD4<sup>+</sup> and CD8<sup>+</sup> T cells and to neutralize IFN- $\gamma$ . 60% of these mice developed progressively growing tumors whereas no tumors were seen in the control mice. Importantly, suppression of NK cell function did not induce tumor outgrowth, indicating that suppression of the adaptive immune response is influential. The authors used mice deficient in recombination-activating genes (Rag1<sup>-/-</sup> or Rag2<sup>-/-</sup> mice), which have innate but no adaptive immune response. When subjected to the same MCA and monoclonal antibody protocol, very few of these mice developed late-onset tumors. In mice that did develop late-onset tumors, the time to tumor outgrowth was prolonged compared with that of the tumors that grew out in wild-type mice treated with antibodies against CD4<sup>+</sup>, CD8<sup>+</sup> and IFN- $\gamma$ . The more rapid outgrowth of tumors in the wild-type immunosuppressed mice indicate that the tumors probably have fully transformed cells that can proliferate in the absence of the adaptive immune response. This was further supported by the fact that atypical fibroblast-like cells that grew out of the stable MCA-generated mass from the wild-type mice formed tumors when injected into Rag2<sup>-/-</sup> mice. However, some of the control wild-type mice developed late-onset sarcoma, indicating that these might arise from cells that had escaped equilibrium. In agreement with cancer immunoediting, cells explanted from these tumors should be able to evade the immune response in syngeneic mice, unlike those with small masses, which should be immunogenic. Indeed, most mice developed tumors when injected with cells from the late-onset sarcomas, whereas up to 51% of the cells from the small masses were rejected. These results clearly indicate that the immune system can maintain tumors in a state of equilibrium and that cells escaping this process are more likely to evade the immune response.